Announcements
- Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
- Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
- Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
- Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
- Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
- Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
- Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
- Akari Therapeutics to Present at Emerging Growth Conference
- Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit
- Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
More ▼
Key statistics
As of last trade, Akari Therapeutics PLC (CLA:BER) traded at 1.97, 98.99% above the 52 week low of 0.99 set on Apr 17, 2024.
52-week range
Open | 1.77 |
---|---|
High | 1.97 |
Low | 1.72 |
Bid | 1.67 |
Offer | 2.06 |
Previous close | 1.84 |
Average volume | 0.00 |
---|---|
Shares outstanding | 396.18k |
Free float | 330.01k |
P/E (TTM) | -- |
Market cap | 15.13m USD |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 23 2024 14:39 BST.
More ▼